2543-6368

Blood Science

Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins

View prefix report (10.1097)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 295 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact295 DOIs
2

Add abstracts to 100 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact100 DOIs
3

Deposit reference lists for 15 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact15 DOIs

DOIs for this ISSN

Showing the top 5 of 295 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 PD-L1: expression regulation (10.1097/bs9.0000000000000149)
ORCID
46.28 70
2 The regulators of BCR signaling during B cell activation (10.1097/bs9.0000000000000026)
ORCID
45.32 64
3 CAR-T cell therapy: Where are we now, and where are we headi… (10.1097/bs9.0000000000000173)
ORCID
43.90 56
4 Will immune therapy cure acute myeloid leukemia? (10.1097/bs9.0000000000000024)
Abstract ORCID
42.25 6
5 T cell metabolism in graft-versus-host disease (10.1097/bs9.0000000000000035)
ORCID License
42.25 6
6 CT103A, a forward step in multiple myeloma immunotherapies (10.1097/bs9.0000000000000068)
Abstract ORCID
42.25 6
7 Disulfiram, an aldehyde dehydrogenase inhibitor, works as a… (10.1097/bs9.0000000000000117)
ORCID
41.33 44
8 LILRB4, an immune checkpoint on myeloid cells (10.1097/bs9.0000000000000109)
ORCID
39.78 38
9 Clinical characteristics and survival of patients with IgD m… (10.1097/bs9.0000000000000066)
Abstract ORCID
38.91 5
10 Targeting macrophages to reprogram the tumor immune microenv… (10.1097/bs9.0000000000000203)
Abstract ORCID
38.91 5
11 MicroRNAs: discovery, breakthrough, and innovation (10.1097/bs9.0000000000000210)
Abstract ORCID
38.91 5
12 Cell cycle regulation and hematologic malignancies (10.1097/bs9.0000000000000009)
ORCID
38.60 34
13 T cell response in patients with COVID-19 (10.1097/bs9.0000000000000050)
ORCID
36.93 29
14 Spatially resolved transcriptomics: advances and application… (10.1097/bs9.0000000000000141)
ORCID
36.56 28
15 Deciphering the hematopoietic cell ecosystem (10.1097/bs9.0000000000000211)
Abstract References ORCID
35.78 2
16 Advances in measuring DNA methylation (10.1097/bs9.0000000000000098)
ORCID
35.37 25
17 Macrophages in leukemia microenvironment (10.1097/bs9.0000000000000014)
ORCID
34.95 24
18 The importance of genomic predictors for clinical outcome of… (10.1097/bs9.0000000000000075)
Abstract ORCID
34.95 4
19 Regulation of megakaryopoiesis by bone marrow macrophage pol… (10.1097/bs9.0000000000000090)
Abstract ORCID
34.95 4
20 NEK2, a promising target in TP53 mutant cancer (10.1097/bs9.0000000000000106)
Abstract ORCID
34.95 4
21 Dynamic frailty-tailored therapy (DynaFiT): A proof-of-conce… (10.1097/bs9.0000000000000208)
Abstract ORCID
34.95 4
22 Immune therapy: a new therapy for acute myeloid leukemia (10.1097/bs9.0000000000000140)
ORCID
34.04 22
23 The role of cholesterol metabolism in leukemia (10.1097/bs9.0000000000000016)
ORCID
33.56 21
24 Epigenetic regulation of hematopoietic stem cell homeostasis (10.1097/bs9.0000000000000018)
ORCID
33.56 21
25 Erythroblast island macrophages: recent discovery and future… (10.1097/bs9.0000000000000017)
ORCID
33.06 20
26 Engineered human pluripotent stem cell-derived natural kille… (10.1097/bs9.0000000000000023)
ORCID
33.06 20
27 MYC in T-cell acute lymphoblastic leukemia: functional impli… (10.1097/bs9.0000000000000073)
ORCID
33.06 20
28 Effects of genetic polymorphisms on methotrexate levels and… (10.1097/bs9.0000000000000142)
ORCID
31.38 17
29 Long non-coding RNAs during normal erythropoiesis (10.1097/bs9.0000000000000027)
ORCID
30.76 16
30 Artificial intelligence and its applications in digital hema… (10.1097/bs9.0000000000000130)
ORCID
30.76 16
31 Machine learning algorithm as a prognostic tool for Epstein-… (10.1097/bs9.0000000000000143)
ORCID
30.76 16
32 Aptamer technology: a new approach to treat lymphoma? (10.1097/bs9.0000000000000033)
ORCID License
30.10 3
33 The impact of venetoclax based regimens in the preemptive of… (10.1097/bs9.0000000000000101)
Abstract ORCID
30.10 3
34 Treatment of STAT5b-RARA positive acute promyelocytic leukem… (10.1097/bs9.0000000000000111)
ORCID
30.10 15
35 Epitranscriptomics in myeloid malignancies (10.1097/bs9.0000000000000124)
Abstract ORCID
30.10 3
36 Big stride in gene therapy for hemophilia B in China (10.1097/bs9.0000000000000150)
Abstract ORCID
30.10 3
37 Interleukin-12 supports in vitro self-renewal of long-term h… (10.1097/bs9.0000000000000002)
ORCID
29.40 14
38 The correlation between Flt3-ITD mutation in dendritic cells… (10.1097/bs9.0000000000000092)
ORCID
29.40 14
39 Sex differences in normal and malignant hematopoiesis (10.1097/bs9.0000000000000133)
ORCID
29.40 14
40 Erythroferrone in focus: emerging perspectives in iron metab… (10.1097/bs9.0000000000000198)
ORCID
29.40 14
41 Hematopoietic stem cell metabolism and stemness (10.1097/bs9.0000000000000012)
ORCID
28.65 13
42 Integrated genomic analyses identify high-risk factors and a… (10.1097/bs9.0000000000000102)
ORCID
28.65 13
43 Tumor heterogeneity of acute myeloid leukemia: insights from… (10.1097/bs9.0000000000000015)
ORCID
27.85 12
44 Molecular mechanisms for stemness maintenance of acute myelo… (10.1097/bs9.0000000000000020)
ORCID
27.85 12
45 Mature plasmacytoid dendritic cells associated with acute my… (10.1097/bs9.0000000000000097)
ORCID
27.85 12
46 The disruption of hematopoiesis in tumor progression (10.1097/bs9.0000000000000001)
ORCID
26.98 11
47 Inflammation and hematopoietic stem cells aging (10.1097/bs9.0000000000000063)
ORCID
26.98 11
48 Gut microbiota plays pivotal roles in benign and malignant h… (10.1097/bs9.0000000000000200)
ORCID
26.98 11
49 Current status and hurdles for CAR-T cell immune therapy (10.1097/bs9.0000000000000025)
ORCID
26.03 10
50 Zebrafish for thrombocytopoiesis- and hemostasis-related res… (10.1097/bs9.0000000000000043)
ORCID
26.03 10